180 related articles for article (PubMed ID: 37051245)
1. Basic characterization of antibodies targeting receptors of the tumor necrosis factor receptor superfamily.
Zaitseva O; Anany M; Wajant H; Lang I
Front Immunol; 2023; 14():1115667. PubMed ID: 37051245
[TBL] [Abstract][Full Text] [Related]
2. Analysis of FcγR-Dependent Agonism of Antibodies Specific for Receptors of the Tumor Necrosis Factor (TNF) Receptor Superfamily (TNFRSF).
Medler J; Wajant H
Methods Mol Biol; 2021; 2248():81-90. PubMed ID: 33185869
[TBL] [Abstract][Full Text] [Related]
3. Analysis of Ligand-Receptor Interactions Using Bioluminescent TNF Superfamily (TNFSF) Ligand Fusion Proteins.
Kucka K; Medler J; Wajant H
Methods Mol Biol; 2021; 2248():185-200. PubMed ID: 33185876
[TBL] [Abstract][Full Text] [Related]
4. Quantitative analysis of cell surface antigen-antibody interaction using Gaussia princeps luciferase antibody fusion proteins.
Kums J; Nelke J; Rüth B; Schäfer V; Siegmund D; Wajant H
MAbs; 2017 Apr; 9(3):506-520. PubMed ID: 28095113
[TBL] [Abstract][Full Text] [Related]
5. Receptor Oligomerization and Its Relevance for Signaling by Receptors of the Tumor Necrosis Factor Receptor Superfamily.
Kucka K; Wajant H
Front Cell Dev Biol; 2020; 8():615141. PubMed ID: 33644033
[TBL] [Abstract][Full Text] [Related]
6. Binding Studies of TNF Receptor Superfamily (TNFRSF) Receptors on Intact Cells.
Lang I; Füllsack S; Wyzgol A; Fick A; Trebing J; Arana JA; Schäfer V; Weisenberger D; Wajant H
J Biol Chem; 2016 Mar; 291(10):5022-37. PubMed ID: 26721880
[TBL] [Abstract][Full Text] [Related]
7. TNFRSF receptor-specific antibody fusion proteins with targeting controlled FcγR-independent agonistic activity.
Medler J; Nelke J; Weisenberger D; Steinfatt T; Rothaug M; Berr S; Hünig T; Beilhack A; Wajant H
Cell Death Dis; 2019 Mar; 10(3):224. PubMed ID: 30833543
[TBL] [Abstract][Full Text] [Related]
8. Studies of binding of tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) to fibroblast growth factor inducible 14 (Fn14).
Fick A; Lang I; Schäfer V; Seher A; Trebing J; Weisenberger D; Wajant H
J Biol Chem; 2012 Jan; 287(1):484-495. PubMed ID: 22081603
[TBL] [Abstract][Full Text] [Related]
9. CD40- and 41BB-specific antibody fusion proteins with PDL1 blockade-restricted agonism.
Medler J; Kucka K; Melo V; Zhang T; von Rotenhan S; Ulrich J; Bremer E; Hudecek M; Beilhack A; Wajant H
Theranostics; 2022; 12(4):1486-1499. PubMed ID: 35198053
[No Abstract] [Full Text] [Related]
10. Principles of antibody-mediated TNF receptor activation.
Wajant H
Cell Death Differ; 2015 Nov; 22(11):1727-41. PubMed ID: 26292758
[TBL] [Abstract][Full Text] [Related]
11. CD40- and CD95-specific antibody single chain-Baff fusion proteins display BaffR-, TACI- and BCMA-restricted agonism.
Nelke J; Medler J; Weisenberger D; Beilhack A; Wajant H
MAbs; 2020; 12(1):1807721. PubMed ID: 32840410
[TBL] [Abstract][Full Text] [Related]
12. Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody.
Zhang D; Goldberg MV; Chiu ML
J Biol Chem; 2016 Dec; 291(53):27134-27146. PubMed ID: 27856634
[TBL] [Abstract][Full Text] [Related]
13. Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies.
Bulliard Y; Jolicoeur R; Windman M; Rue SM; Ettenberg S; Knee DA; Wilson NS; Dranoff G; Brogdon JL
J Exp Med; 2013 Aug; 210(9):1685-93. PubMed ID: 23897982
[TBL] [Abstract][Full Text] [Related]
14. Fundamental Characterization of Antibody Fusion-Single-Chain TNF Recombinant Proteins Directed against Costimulatory TNF Receptors Expressed by T-Lymphocytes.
Nagai H; Azuma M; Sato A; Shibui N; Ogawara S; Tsutsui Y; Suzuki A; Wakaizumi T; Ito A; Matsuyama S; Morita M; Hikosaka Kuniishi M; Ishii N; So T
Cells; 2023 Jun; 12(12):. PubMed ID: 37371066
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast growth factor inducible (Fn14)-specific antibodies concomitantly display signaling pathway-specific agonistic and antagonistic activity.
Salzmann S; Seher A; Trebing J; Weisenberger D; Rosenthal A; Siegmund D; Wajant H
J Biol Chem; 2013 May; 288(19):13455-66. PubMed ID: 23532848
[TBL] [Abstract][Full Text] [Related]
16. Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities.
Waight JD; Gombos RB; Wilson NS
Hum Antibodies; 2017; 25(3-4):87-109. PubMed ID: 28085016
[TBL] [Abstract][Full Text] [Related]
17. Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein.
Boado RJ; Hui EK; Lu JZ; Zhou QH; Pardridge WM
J Biotechnol; 2010 Mar; 146(1-2):84-91. PubMed ID: 20100527
[TBL] [Abstract][Full Text] [Related]
18. Anti-Fn14 Antibody-Conjugated Nanoparticles Display Membrane TWEAK-Like Agonism.
Aido A; Zaitseva O; Wajant H; Buzgo M; Simaite A
Pharmaceutics; 2021 Jul; 13(7):. PubMed ID: 34371763
[TBL] [Abstract][Full Text] [Related]
19. HERA-GITRL activates T cells and promotes anti-tumor efficacy independent of FcγR-binding functionality.
Richards DM; Marschall V; Billian-Frey K; Heinonen K; Merz C; Redondo Müller M; Sefrin JP; Schröder M; Sykora J; Fricke H; Hill O; Gieffers C; Thiemann M
J Immunother Cancer; 2019 Jul; 7(1):191. PubMed ID: 31324216
[TBL] [Abstract][Full Text] [Related]
20. Lack of Evidence for a Direct Interaction of Progranulin and Tumor Necrosis Factor Receptor-1 and Tumor Necrosis Factor Receptor-2 From Cellular Binding Studies.
Lang I; Füllsack S; Wajant H
Front Immunol; 2018; 9():793. PubMed ID: 29740434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
